Navigation Links
AEterna Zentaris Announces Outcome of Management's Strategic Review
Date:10/2/2007

QUEBEC CITY, QC, Oct. 2 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), a global biopharmaceutical company focused on endocrine therapy and oncology, will announce today at 11: 00 a.m. Eastern Time, during a live webcast presentation and conference call hosted by President and Chief Executive Officer, David J. Mazzo, Ph.D., the outcome of management's review of the Company's pipeline and business operations along with key elements of the new strategic plan implemented to achieve short-term and long-term success.

David J. Mazzo, President and Chief Executive Officer of AEterna Zentaris stated, "Over the past four months, our Executive Team has been tasked with completing a thorough review of our extensive pipeline and business operations with the goal of creating a strategy optimized for success. As a result of this extensive exercise, we established a harmonized global vision and elucidated our strategic imperatives. Based on a rigorous assessment of the value of our assets, our abilities and resources, the probability of success and return on investment potential of each of our product candidates and our objective to maximize shareholder value, we additionally established a set of priorities and plans to achieve our vision."

During the live webcast, the company will discuss in detail the following fundamentals of their strategic plan.

- AEterna Zentaris is now a multinational company with a clear vision to

eventually become a fully integrated biopharmaceutical company (without

commercial manufacturing). The necessary resources have been identified

and allocated to achieve business success.

- AEterna Zentaris has prioritized its pipeline, developed a partnering

strategy and determined the value of its most immediate assets:

Cetrorelix

Cetrorelix, currently in a Phase 3 program for benign prostatic

hyperplasia (BPH), is clearly the Company's highest priority, being

the asset with the largest combination of probability of success,

proximity to launch and potential medical and commercial value. The

Company has decided to seek a commercialization partner for

cetrorelix, which, in this indication, has potential for base case

peak annual sales of over $500 million in the United States market

alone. After defining the critical path to registration, the Company

expects to launch cetrorelix in the BPH indication in 2011.

Furthermore, after optimization of formulation and trial design, the

company plans to move into Phase 2b in the endometriosis indication

and will announce timelines relative to this program in the near

future. As was announced in May 2007, the rights to cetrorelix in the

endometriosis indication were regained from Solvay. The decision to

proceed with development was made based on:

a) the proven safety and efficacy of Cetrotide(R)

b) the overall database from preclinical and clinical studies in

endometriosis

c) the large unmet medical needs and commercial opportunity in the

area of endometriosis.

Additionally, as with the BPH indication, AEterna Zentaris will

eventually seek a commercialization partner as cetrorelix has the

potential for base case peak annual sales of approximately

$200 million in the U.S. market alone in the endometriosis

indication.

AEZS-108

AEterna Zentaris has established its cytotoxic conjugate, AEZS-108,

as its highest earlier-stage priority, and will therefore initiate a

Phase 2 trial with this compound in a both endometrial and ovarian

cancers before year end. The Company feels AEZS-108 has large market

opportunities that could compare to those for doxorubicin.

- The Company provided clarity regarding its partnered development

programs. The Company will minimize internal spend on partnered

programs while continuing to respect its contractual obligations to

support its partners for the development of ozarelix, perifosine,

AEZS-127 and AEZS-130. AEterna Zentaris will employ a "piggy back"

registration strategy to bring these products to market in the

territories where is retains rights as commercial opportunity size

dictates.

- The Company prioritized the advancement of preclinical and very

early-stage development programs based on risk-adjusted maximum market

potential.

- The Company established a clear global partnering strategy moving

forward:

- All commercially viable projects will be ideally developed internally

through proof-of-concept in man

- Asia (especially Japan) remains a market of interest for AEZS

- The Company also identified non-core assets and will actively seek to

monetize/divest these assets as a potential source of non-dilutive

funding.

- The Company provided updated guidance for the 2007 total expected burn

in a range of $25-$27 million. Additionally, in an effort to ensure

financial flexibility, the Company recently filed a shelf prospectus.

"It has been our guiding principle to communicate the complete picture of AEterna Zentaris as it is and as it is planned to be with updated timelines, priorities, key issues and expectations. After a rigorous review of the projects, risks, plans and commercial opportunities, we are more bullish than ever about the unrealized intrinsic value of AEZS and our ability to unlock it to the benefit of patients and shareholders," concluded Dr. Mazzo.

Conference call and Webcast

Participants may access the live webcast via the Company's website at http://www.aeternazentaris.com in the "Investors" section, or by telephone using the following numbers: 416-644-3414, 514-807-8791 or 800-733-7571.

A replay of the webcast will also be available on the Company's website for a period of 30 days.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization.

News releases and additional information are available at http://www.aeternazentaris.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... Palo Alto, CA (PRWEB) , ... September 20, ... ... and public interest organization focused on molecular manufacturing and other transformative technologies, announced ... categories, one for Experiment and the other for Theory in nanotechnology/molecular manufacturing. , ...
(Date:9/19/2017)... ... 19, 2017 , ... Participants of this educational webinar will ... Along with the advantages and disadvantages of ductless, filtered fume hoods, they will ... laboratory. , Attendees will learn from an industry expert about the different types ...
(Date:9/19/2017)... ... September 19, 2017 , ... The new and improved Oakton® pocket ... testers even stand upright with a new cap design that is versatile, functional and ... field who need to test water quality. , The Oakton pocket testers have many ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... is pleased to announce the recipients of its 2017 Science Student Award. The ... leadership qualities, and involvement with community service defray the costs of obtaining their ...
Breaking Biology Technology:
(Date:8/15/2017)... HAMPTON, Va. , Aug. 15 2017   ivWatch LLC ... effectiveness of intravenous (IV) therapy, today announced receipt of its ISO ... (QMS) developed by the International Organization for Standardization (ISO┬«). ... ivWatch Model 400 Continuous Monitoring device for ... "This ...
(Date:5/23/2017)... 2017  Hunova, the first robotic gym for the rehabilitation and functional ... in Genoa, Italy . The first 30 robots will ... USA . The technology was developed and patented at ... IIT spin-off Movendo Technology thanks to a 10 million euro investment from ... click: ...
(Date:4/19/2017)... New York , April 19, 2017 ... competitive, as its vendor landscape is marked by the ... the market is however held by five major players ... Safran. Together these companies accounted for nearly 61% of ... of the leading companies in the global military biometrics ...
Breaking Biology News(10 mins):